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Abstract 
Pancreatic cancer is characterized excessive desmoplasia, which occupies 80% of 
pancreatic cancer tissue and mainly consists of pancreatic stellate cells (PSCs). 
Desmoplasia has been shown to play an important role in the progression, invasion, and 
metastasis of pancreatic cancer and has been implicated in the development of 
resistance to chemotherapy and radiotherapy. Moreover, growth factors, which bind to 
receptor tyrosine kinases (RTKs) and activate downstream signaling, are one of the 
components modulating the interactions between pancreatic cancer cells (PCCs) and 
PSCs. Therefore, blocking RTKs, which are highly expressed in both PCCs and PSCs, 
could suppress cancer progression. In this study, I profiled the expression of RTKs with 
quantitative targeted absolute proteomics using liquid chromatography tandem mass 
spectrometry (LC-MS/MS) in PCCs and PSCs. In PCCs, epidermal growth factor 
receptor (EGFR) and hepatocyte growth factor receptor (MET) levels were elevated 
compared with those in PSCs. Additionally, in PSCs, platelet-derived growth factor 
receptor beta (PDGFR!) and MET were upregulated compared with other RTKs. 
Conditioned medium from PSCs promoted the proliferation of PCCs, and vice versa. In 
addition, MK2461, a multikinase inhibitor targeting MET and PDGFR!, suppressed the 
effects of conditioned medium on PCCs and PSCs. Finally, MK2461 significantly 
inhibited tumor growth in mice co-injected with PCCs and PSCs. In conclusion, 
PDGFR! and MET may play a critical role in the interaction between PCCs and PSCs, 
which was modulated by MK2461. Therefore, MK2461 may have therapeutic potential 









Pancreatic cancer is a highly aggressive disease characterized by an extremely 
poor prognosis. Despite recent developments in the diagnosis and therapeutic 
management of pancreatic cancer, the overall 5-year survival rate is less than 5% 1), in 
part due to the poor response of pancreatic cancer to most chemotherapeutic agents and 
radiotherapy. Therefore, improving our understanding of the development and 
progression of pancreatic cancer is essential 2). 
Pancreatic cancer is characterized by excessive desmoplasia, which occupies 
80% of pancreatic cancer tissue 3). However, most previous studies have focused on 
cancer cells themselves, and the abundant desmoplasia has been largely ignored 4). The 
desmoplasia is thought to be essential for the invasion, metastasis, and 
chemotherapeutic resistance of pancreatic cancer 5-10) and has been shown to be 
comprised primarily of pancreatic stellate cells (PSCs), which are observed in the 
interlobular areas and the peri-acinar lesions of the pancreas 11). PSCs are transformed 
from a quiescent state into myofibroblast-like cells in response to cytokines and growth 
factors, such as transforming growth factor (TGF) !1, platelet-derived growth factor 
(PDGF), and fibroblast growth factor (FGF), which are secreted from inflammatory 
cells and cancer cells. Activated PSCs are characterized by high expression of "-smooth 
muscle actin (SMA), and once PSCs are activated by pancreatic cancer cells (PCCs), 
these cells are suggested to remain in the active state via autonomous signaling loops 4, 
12, 13). Activated PSCs produce abundant extracellular matrix (ECM), cytokines, and 
growth factors, and the production of ECM contributes to excessive fibrosis, thereby 
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leading to interstitial hypertension, inefficient drug delivery 14-16), and resistance to 
radiotherapy 17). Furthermore, secreted growth factors from activated PSCs, such as 
PDGF, FGF, insulin-like growth factor (IGF), hepatocyte growth factor (HGF), and 
TGF!1, promote PCC proliferation, invasion, and migration, partially through induction 
of the epithelial-to-mesenchymal transition (EMT) 10, 18, 19). In an in vivo study, PCCs 
subcutaneously injected with PSCs were shown to grow more rapidly than PCCs 
injected alone 20). Moreover, in an orthotopic model, co-injection of PCCs with PSCs 
resulted in increased tumor incidence, metastasis, and tumor size 21). In addition, PCC 
stimulation increases the secretion of growth factors and ECM components from PSCs 
18). Thus, reciprocal stimulation of PCCs and PSCs is essential in the progression of 
pancreatic cancer.  
Altered expression of various receptor tyrosine kinases (RTKs) has been 
observed in several types of cancer, and the expression of some RTKs correlates with 
patient prognosis 22-24). Growth factors mediate their effects by binding to various RTKs. 
Thus, profiling the expression of RTKs in both PCCs and PSCs may lead to 
identification of growth factors regulating the interaction between PCCs and PSCs.  
MK2461 is a multikinase inhibitor that was developed as ATP-competitive 
inhibitor of activated HGF receptor (MET). This compound effectively inhibits 
constitutive or ligand-dependent phosphorylation of MET and significantly inhibits 
several other RTKs. Moreover, MK2461 exerts significant antitumor activities through 
inhibition of MET, FGF receptor 2 (FGFR2), and PDGF receptor (PDGFR) in vitro and 
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in vivo 25). Therefore, MK2461 may have applications as a potential anticancer agent in 
pancreatic cancer through disruption of RTK signaling in PCCs and PSCs. 
In this study, I sought to identify novel candidate targets for improving the 
therapeutic management of pancreatic cancer. To this end, I measured the expression 
levels of 15 RTKs by quantitative targeted absolute proteomics (QTAP) and analyzed 
the roles of these RTKs in pancreatic cancer. In addition, I examined the effects of 
MK2461 on the PCC-PSC interaction.  
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Materials and Methods 
Cell culture 
PANC-1 cells were obtained from RIKEN BRC CELL BANK (Tsukuba, Japan). 
Capan-2, HPAF-II, BxPC-3, SW1990, and AsPC-1 cells were purchased from 
American Type Culture Collection (ATCC, Manassas, VA, USA). SUIT-2, KLM-1, 
PK-1, and PK-8 cells were obtained from the Cell Resource Center for Biomedical 
Research, Tohoku University (Sendai, Japan). All of the pancreatic cancer cell lines 
used in this study have KRAS mutation. TIG-1-20, human fetal lung fibroblast, were 
obtained from the Cell Resource Center for Biomedical Research, Tohoku University. 
Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Nichirei 
Pharmaceutical, Tokyo, Japan) containing 10% fetal bovine serum (FBS) with 4.5 g/L 
glucose, 1.5 g/L NaHCO3, 70 µg/mL penicillin, 100 µg/mL streptomycin, and 2.5 
µg/mL amphotericin at 37°C in a humidified atmosphere of 5% CO2.  
Reagents and antibodies 
All of the standard peptides and stable isotope-labeled peptides used for QTAP were 
synthesized by Thermo Fisher Scientific (Sedantrade, Germany). Sequencing-grade 
modified trypsin (Promega, Madison WI, USA) was used for trypsin digestion of the 
targeted proteins. MK2461 was purchased from Selleck (Houston, TX, USA). All other 
reagents were commercial products of analytical grade unless specifically described. 
The antibodies used in this study included anti-phospho-MET (Tyr1234/Tyr1235), 
anti-AKT, anti-phospho-AKT (Ser473), anti-extracellular signal-regulated kinase 1/2 
(ERK1/2), anti-phospho-ERK1/2 (Thr202/Tyr204), anti-GAPDH, anti-PDGFR!, and 
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anti-vimentin from Cell Signaling Technology (Danvers, MA, USA); anti-MET and 
anti-"-SMA from Abcam (Cambridge, MA, USA); anti-phospho-PDGFR! (Tyr1021) and 
anti-cytokeratin19 from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-Ki-67 
from Nichirei Biosciences (Tokyo, Japan); and Alexa Fluor 488-conjugated anti-rabbit 
IgG antibody, Alexa Fluor 555-conjugated anti-mouse IgG antibody, horseradish 
peroxidase (HRP)-linked anti-rabbit IgG antibody, and HRP-conjugated anti-mouse IgG 
antibody from Cell Signaling Technology. 
Human samples 
The pancreatic tissue blocks used in this study were obtained from patients undergoing 
surgery at Tohoku University Hospital. All patients were diagnosed with pancreatic 
cancer by biopsy before surgery. The samples were obtained in accordance with the 
policies and practices of the Ethics Committee of Tohoku University Graduate School 
of Medicine, and patients provided informed consent.  
Primary culture of PSCs 
PSCs were prepared from pancreatic cancer tissues by the outgrowth method 20). The 
tissues were minced into 0.5–1 mm3 pieces and seeded in 6-well uncoated culture plates 
in the presence of 10%–20% FBS in a 1:1 (v/v) mixture of DMEM and Ham’s F12 
medium (ATCC) containing 70 µg/mL penicillin, 100 µg/mL streptomycin, and 2.5 
µg/mL amphotericin. Tissue blocks were cultured at 37°C in a 5% CO2/air humidified 
atmosphere. After incubation for 24 h, the tissue blocks were transferred to new 6-well 
plates, and PSCs grew out of the blocks a few days after seeding. After reaching 
confluence, PSCs were trypsinized and passaged. The purity of the cells was determined 
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by the immunofluorescence for "-SMA and vimentin, as well as morphology 
(spindle-shaped cells with cytoplasmic extensions) 26). In this study, all of the 
established PSCs were used at passages 3–6. 
Preparation of conditioned medium 
Conditioned medium was prepared to evaluate the PCC-PSC interaction 21, 27). SUIT-2 
and PANC-1 cells were grown to 70%–80% confluence, and PSCs were grown to 90%–
100% confluence in DMEM containing 10% FBS. The medium was then changed to 
serum-free medium, which was collected after 24–48 h, passed through a 0.22-µm pore 
size filter (Thermo Scientific, Waltham, MA, USA), and concentrated with a 3-kDa 
Ultrafiltration membrane (Millipore, Billerica, MA, USA). Protein concentrations were 
determined by the Lowry method (Bio-Rad, Hercules, CA, USA), and aliquots were 
stored at #80°C until use. 
Immunofluorescence staining of PSCs 
For immunofluorescence staining, PSCs were seeded in 2-well glass coverslips (IWAKI 
Scitech Division, Tokyo, Japan). PSCs were then fixed with 4% paraformaldehyde for 
15 min at room temperature and blocked with 5% normal goat serum and 0.3% Triton 
X-100 in phosphate-buffered saline (PBS) for 1 h at room temperature after washing 
with PBS three times for 5 min each wash. PSCs were then incubated with mouse 
monoclonal anti-"-SMA and rabbit monoclonal anti-vimentin antibodies at 4°C 
overnight, washed with PBS (three times for 5 min each), and incubated with Alexa 
Fluor 488-conjugated anti-rabbit IgG antibodies and Alexa Fluor 555-conjugated 
anti-mouse IgG antibodies for 2 h at room temperature in the dark. The antibodies were 
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diluted in PBS containing 1% bovine serum albumin (BSA) and 0.3% Triton X-100 
according to the manufacturer’s instructions. PSCs were then washed with PBS (three 
times for 5 min each) and mounted with Prolong Anti-fade reagent with 
4$,6-diamidino-2-phenylindole (DAPI; Life Technologies). Staining was observed using 
a confocal laser-scanning microscope (CLSM; C2si, Nikon, Japan). 
Preparation of plasma membrane fractions from cells 
Plasma membrane fractions were extracted as described previously 28, 29). Cells were 
grown to confluence in 10-cm2 dishes, scraped, and suspended in Suspension buffer (10 
mM Tris-HCl [pH 7.4], 250 mM sucrose, 1 mM EGTA) containing protease inhibitor 
cocktail (Sigma-Aldrich, St. Louis, MO, USA). Then, cells were lysed by nitrogen 
cavitation at 750 psi for 15 min at 4°C and centrifuged at 10,000 % g for 10 min at 4°C 
to remove debris. The supernatants were collected and centrifuged at 100,000 % g for 40 
min at 4°C, and the resulting pellets were resuspended in Suspension buffer. The 
suspensions were layered on top of a 38% (w/v) sucrose solution and centrifuged at 
100,000 % g for 40 min at 4°C. The resulting turbid layer at the interface was collected 
and centrifuged at 100,000 % g for 40 min. The pellets were resuspended in Suspension 
buffer as the plasma membrane fraction. Protein concentrations were determined with 
the Lowry method (Bio-Rad). 
Preparation of plasma membrane fractions from pancreatic tissues 
Pancreatic tissues were minced into 1-mm3 pieces and added to Hypotonic buffer (10 
mM NaCl, 1.5 mM MgCl2, 10 mM Tris-HCl, pH 7.4) containing protease inhibitor 
cocktail (Sigma Chemical Co.) and PMSF (125 mM in isopropanol). Then, tissues were 
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homogenized using a Potter-Elvehjem Tissue Grinder on ice and lysed by nitrogen 
cavitation at 750 psi for 15 min at 4°C. The homogenates were centrifuged at 10,000 % 
g for 10 min at 4°C to remove debris, and the supernatants were collected. The same 
procedures were then used as for the preparation of the plasma membrane fraction from 
cells. 
QTAP by liquid chromatography tandem mass spectrometry (LC-MS/MS) 
The absolute amount of membrane protein was quantified using a multiplex 
SRM/MRM method, as described previously 28-30). The protein samples were denatured 
with alkylation buffer (7 M guanidine hydrochloride, 10 mM EDTA-Na, 0.5 M 
Tris-HCl, pH 8.5), followed by reduction and S-carbamoylmethylation. The alkylated 
proteins were digested with sequence-grade modified trypsin (Promega) at 37°C for 16 
h. Trypsin-digested samples were mixed with a stable isotope-labeled peptide mixture 
as internal standard peptides and acidified with formic acid. Then, samples were 
centrifuged at 15,000 rpm, and the supernatants were injected into the high-performance 
liquid chromatography (HPLC) system (Agilent 1200 HPLC system; Agilent 
Technologies, Santa Clara, CA, USA), which was connected to an ESI-triple 
quadrupole mass spectrometer (QTRAP5500; AB SCIEX, Foster City, CA, USA). C18 
columns (XBridge BEH130 C18, 130 Å, 3.5 &m, 100 % 1.0 mm; Waters, Milford, MA, 
USA) were used for HPLC. The mass spectrometer was set up to run an SRM/MRM 
experiment for peptide detection using a dwell time of 10 ms per SRM/MRM transition. 
The ion counts in the chromatograms were determined by using the quantitation 
procedures in Analyst software version 1.5 (AB Sciex). In the SRM/MRM analysis, 
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each peptide for a targeted protein was monitored with four SRM/MRM transitions 
specific for that peptide. For QTAP, the peak area ratios of the analyte and the stable 
isotope-labeled peptides in each SRM/MRM transition were measured, and quantitative 
values were calculated from the standard curve (R2 > 0.98). To construct standard 
curves, a dilution series of standard peptide with a fixed amount of internal standard 
peptide was injected into an LC-MS/MS instrument. Unless otherwise indicated, at least 
three of the four SRM/MRM transitions needed to be measurable in order for a 
prototypic peptide to be judged as confirmed and for a quantitative value to be assigned. 
The value of the quantification limit of each protein (fmol/mg protein) was determined 
as described previously 28-30). Peptide sequences for targeted proteins and MRM 
transitions (m/z values) are shown in Table 1. 
Proliferation assay 
SUIT-2 and PANC-1 cells were seeded at 3000 cells/well, and PSCs were seeded at 
5000 cells/well in 96-well plates. Cells were incubated overnight in DMEM containing 
10% FBS, after which the medium was changed to serum-free medium. Then, different 
concentrations of conditioned medium (0, 0.1, 0.5 mg/mL) and MK2461 (0, 0.1, 1, 3 
µM) were added, and cells were incubated for 48 h. Serum-free medium was added to 
control wells. Following incubation, proliferation was measured using a Cell Counting 
Kit-8 (DOJINDO, Kumamoto, Japan) according to the manufacturer’s instructions. 
Each assay was carried out in triplicate wells and repeated twice. Data are shown as 
percent change compared to the control. 
Western blotting 
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Cells were grown to 70%–80% confluence in DMEM containing 10% FBS, then serum 
starved overnight. Cells were incubated with MK2461 (1 or 3 µM) for 4 h, then 
stimulated with conditioned medium (0.1 or 0.5 mg/mL) for 10 min. Cells were then 
washed with PBS, scraped, and lysed in radio-immunoprecipitation assay (RIPA) buffer 
(Thermo Scientific) (25 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1% sodium 
deoxycholate, 0.1% SDS) containing protease inhibitor cocktail (Roche Diagnostic, 
East Sussex, UK) on ice. Whole cell lysates were centrifuged (20,000 % g; 30 min; 4°C), 
and the supernatants were collected. Protein concentrations were determined by BCA 
protein assays (Thermo Scientific), with BSA as the standard protein. Lysates were 
mixed with Laemmli Sample Buffer (Bio-Rad) (62.5 mM Tris-HCl [pH 6.8], 10% 
glycerol, 1% LDS, 0.005% Bromophenol Blue) and denatured at 95°C for 5 min. Cell 
lysates were then fractionated on 4%–15% SDS-polyacrylamide gels with 
Tris/glycine/SDS buffer (Bio-Rad) and transferred to PVDF membranes (Bio-Rad). 
Membranes were blocked with SuperBlock (TBS) Blocking Buffer (Thermo Scientific) 
for 1 h at room temperature, washed with TBST (TBS, 0.1% Tween-20) three times for 
5 min, and incubated with primary antibodies diluted with TBST containing 5% BSA at 
4°C overnight. Membranes were then washed with TBST three times for 10 min each 
and incubated with corresponding HRP-conjugated secondary antibodies for 1 h at 
room temperature. Detection was facilitated by Clarity Western ECL Substrate 
(Bio-Rad), and the protein bands were observed on an ImageQuant LAS 4000 mini (GE 
Healthcare, Buckinghamshire, UK).  
Invasion assay 
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Invasion assays were carried out with 24-well BD BioCoat Matrigel Invasion Chambers 
(BD Biosciences, Franklin Lakes, NJ, USA). SUIT-2 and PANC-1 cells (2 % 104) were 
resuspended in 500 µL of serum-free medium and seeded in the upper chambers. Lower 
chambers contained 750 µL of conditioned medium (0, 0.1, or 0.5 mg/mL) and 
MK2461 (0, 0.1, 1 µM) in serum-free medium. Cells were incubated for 48 h at 
37°C/5% CO2, and cells that had invaded through the pores to the lower surface were 
fixed and stained with Diff-Quick reagent (Sysmex International Reagents, Kobe, 
Japan). Invaded cells were counted in eight random adjacent fields using a microscope 
(BZ-9000, KEYENCE, Tokyo, Japan). Each experiment was repeated three times. 
Migration assay 
Migration assays were carried out in 24-well Transwell chambers (BD Biosciences). 
SUIT-2 and PANC-1 cells (2 % 104) were seeded in the upper chambers of Transwell in 
500 µL of serum-free medium. Treatments were as described for the invasion assays, 
and analyses were carried out as described for the invasion assays at 24 h after treatment. 
Each experiment was repeated three times. 
In vivo experiments 
To evaluate the effects of MK2461 on the PCC-PSC interaction in vivo, animal 
experiments were performed as previously described 17, 18). All animal experiments were 
reviewed and approved by the Tohoku University Institutional Animal Care and Use 
Committee. Seven-week-old male nude mice (BALB/cAJcl-nu/nu) were obtained from 
CLEA Japan (Tokyo, Japan). Mice were acclimated to the animal housing facility for 1 
week before studies. SUIT-2 cells and PSCs were resuspended in 100 µL of DMEM 
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containing 20% Matrigel (BD Biosciences), and SUIT-2 cells (1 % 106) and PSCs (1 % 
106) were subcutaneously co-injected into the right flanks, while SUIT-2 cells (1 % 106) 
alone were injected into the left flanks. One week later, mice were divided into two 
groups randomly (n = 7 per group) and administered either vehicle or MK-2461 (20 
mg/kg) twice daily for 20 days by oral gavage. MK2461 was diluted in 0.9% saline 
containing 30% PEG400, 1% DMSO, and 1% Tween-80. Tumor sizes were determined 
with calipers, and tumor volumes were calculated using the formula: ' / 6 % (L % W2), 
where L indicates the largest tumor diameter, and W indicates the smallest tumor 
diameter. When the experiment was terminated, subcutaneous tumors were excised and 
weighed.  
Immunofluorescence staining of tumor tissue 
The tumor tissues were resected, fixed with 10% formalin, embedded in paraffin, and 
cut into 5-&m-thick sections. The sections were deparaffinized and rehydrated with a 
series of alcohol solutions of decreasing concentrations. Antigen retrieval for "-SMA 
and cytokeratin19 was performed by heating the slides in a microwave for 15 min in 
citric acid buffer (2 mM citric acid and 9 mM trisodium citrate dehydrate, pH 6.0). 
After blocking with 1% PBS containing 3% BSA and 0.3% Triton X-100, sections were 
incubated with primary antibodies overnight at 4°C. The dilution ranges of primary 
antibodies were follows: "-SMA, 1:100; cytokeratin19, 1:100; Ki-67, 1:100. Sections 
were then washed with PBS three times for 5 min each and incubated with Alexa Fluor 
488-conjugated anti-rabbit IgG antibodies and Alexa Fluor 555-conjugated anti-mouse 
IgG antibodies for 1 h at room temperature in the dark. The antibodies were diluted in 
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PBS containing 1% BSA and 0.3% Triton X-100 according to the manufacturer’s 
instructions. After incubation, sections were washed with PBS three times and 
counterstained with Prolong Anti-fade with DAPI to identify nuclei. Sections were then 
observed with a microscope (BZ-9000, KEYENCE), and the stained cells were counted 
in three random fields. Scale bar, 50 µm. 
Statistical analysis 
Data are shown as the mean ? SEM. Comparisons of paired data were analyzed by 
two-tailed Student’s t tests, and comparisons of over three groups were analyzed by 
one-way analysis of variance (ANOVA) with the Tukey-Kramer multiple comparisons 
test. Differences with P values of less than 0.05 were considered significant. Statistical 














Isolation and identification of PSCs  
PSCs were derived from fresh human pancreatic adenocarcinoma surgical specimens by 
the outgrowth method, and their identities were confirmed by immunofluorescence 
staining for "-SMA or vimentin (Fig. 1A). The isolated cells were stained with "-SMA, 
a marker of activated PSCs, and expressed vimentin, a marker of mesenchymal cells, 
indicating that they were not pancreatic cancer cells. In addition, these cells exhibited a 
spindle-shaped morphology with cytoplasmic extensions, characteristic of 
myofibroblasts. PSCs were isolated from three patients individually and named PSCI, 
PSCII, and PSCIII. Interestingly, "-SMA expression was increased in PSCs compared 
with TIG-1-20 cells, a normal fibroblast cell line, indicating that the isolated PSCs were 
in an activated state (Fig. 1B).   
PCC-PSC interaction on cell proliferation  
To investigate the effects of PSC conditioned medium on PCCs, proliferation assays 
were performed. Three condition media derived from PSCI, PSCII, and PSCIII 
promoted the proliferation of SUIT-2 and PANC-1 cells as compared to the serum-free 
control (Fig. 1C). For all assays, PCC proliferation was increased following exposure to 
PSC conditioned medium (0.5 mg/mL) as compared with the serum-free control.  
Reciprocally, the conditioned medium from both SUIT-2 and PANC-1 cells 
significantly increased PSCI and PSCII proliferation compared to the serum-free 
controls in a concentration-dependent manner (Fig. 1D).  
Comparison of cell proliferation induced by paracrine and autocrine secretions 
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To elucidate whether paracrine or autocrine effects were modulating the proliferation of 
PCCs in our experiment, I performed proliferation assays using conditioned medium 
from PCCs or PSCs. SUIT-2 and PANC-2 cell proliferation rates were significantly 
increased in the presence of PSCI conditioned medium as compared to SUIT-2 or 
PANC-1 conditioned medium at 0.5 mg/mL, respectively (Fig. 2A). Furthermore, 
SUIT-2 and PANC-1 conditioned media (0.1 or 0.5 mg/mL) significantly accelerated 
the proliferation of PSCIs compared to PSCI conditioned medium (Fig. 2B). Therefore, 
paracrine signaling was more effective at inducing proliferation in both PCCs and 
PSCs.  
Expression levels of membrane RTKs in pancreatic cancer cell lines, PSCs, and 
pancreatic cancer tissues 
Next, I analyzed the expression levels of 15 RTKs by QTAP in plasma membrane 
fractions from 10 human pancreatic cancer cell lines, three primary cultured PSCs 
(PSCI, PSCII, PSCIII), pancreatic cancer tissues obtained from Patient 1-17 (PT1-17), 
and three normal pancreatic tissues obtained from normal noncancerous lesion of 
surgical specimens from Patient 1-3 (NT1-3) (Table 2). EGFR and MET were detected 
in all of the pancreatic cancer cell lines, while EGFR, PDGFR!, and MET were 
detected in the three PSCs. Moreover, EGFR and PDGFR! were detected in all 17 
pancreatic cancer tissues, and MET was detected in 11 pancreatic cancer tissues 
(64.7%). In the three noncancerous tissues, only EGFR was detected. Na+/K+ ATPase 
was detected in all of the samples. 
EGFR expression was about 10–20-fold higher in most pancreatic cancer cell 
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lines than in PSCs and pancreatic cancer tissues (Fig. 3A). In eight pancreatic cancer 
cell lines, the expression levels of PDGFR! were under the detection limit; however, 
this RTK was detected in all of the PSCs and pancreatic cancer tissues (Fig. 3A). 
Expression levels of PDGFR! were equivalent between PSCs and pancreatic cancer 
tissues. MET expression levels in pancreatic cancer cell lines were higher than those in 
PSCs and pancreatic cancer tissues (Fig. 3A).  
Next, I compared the expression levels of RTKs between pancreatic cancer 
tissues (PT1-3) and normal pancreatic tissues (NT1-3). Expression levels of EGFR in 
pancreatic cancer tissues were 2.6–4.9-fold higher than those in noncancerous tissues 
(Fig. 3B). The expression levels of both MET and PDGFR! in noncancerous tissues 
were all under the detection limit, whereas both proteins were detected in pancreatic 
cancer tissues (Fig. 3B). 
MK2461 inhibited the effects of PSC conditioned medium on PCC proliferation by 
suppressing the activation of MET and its downstream signaling   
The RTK profiling experiments revealed that MET was expressed in both PCCs and 
PSCs, but not in normal pancreatic tissue, suggesting that inhibition of MET could 
effectively inhibit the interaction between PSCs and PCCs. In both SUIT-2 and 
PANC-1 cells, significant growth inhibition was observed at 1 µM MK2461 (Fig. 4A). 
Additionally, 0.1 µM MK2461 significantly inhibited SUIT-2 cell proliferation induced 
by PSC conditioned medium. To assess whether MK2461 actually inhibited the effects 
of PSC conditioned medium, I compared the effects of MK2461 in cells treated with or 
without conditioned medium. In SUIT-2 and PANC-1 cells, inhibition of cell growth by 
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1 or 3 µM MK2461, respectively, was significantly higher in cells cultured with PSC 
conditioned medium than in cells cultured in serum-free medium (Fig. 4B). 
Furthermore, I evaluated the effects of MK2461 by western blotting (Fig. 4C). In both 
SUIT-2 and PANC-1 cells, MK2461 inhibited the phosphorylation of MET, AKT, and 
ERK1/2 induced by PSC conditioned medium. 
MK2461 inhibited the effects of PCC conditioned medium on PSC proliferation and 
suppressed activation of PDGFR!, MET, and downstream signaling   
Since PDGFR! and MET were expressed in PSCs and PCC conditioned medium 
induced PSC proliferation, I next evaluated the effects of MK2461 on PSC proliferation. 
In both PSCIs and PSCIIs, MK2461 significantly suppressed the proliferation induced 
by PCC conditioned medium when used at concentrations of 0.1 and 1 µM, respectively 
(Fig. 5A). Moreover, the growth of PSCIs and PSCIIs was significantly inhibited in the 
presence of PCC conditioned medium compared to serum-free medium following 
treatment with 0.1 or 1 µM MK2461, respectively (Fig. 5B). In addition, 
phosphorylation of PDGFR!, MET, ERK1/2, and AKT in PSCs stimulated by PCC 
conditioned medium was inhibited by MK2461 (Fig. 5C). 
MK2461 inhibited the effects of PSC condition medium on PCC invasion and 
migration 
Overexpression or hyperactivation of MET has been associated with increased 
invasiveness in several cancers 31). As PSC conditioned medium activated MET (Fig. 4), 
I next sought to determine whether blocking MET activation affected PCC invasion and 
migration. Indeed, I observed that exposure of SUIT-2 and PANC-1 cells to PSC 
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conditioned medium significantly enhanced the invasion and migration of these cells 
compared to culture under serum-free conditions in a concentration-dependent manner 
(Fig. 6A, B). Furthermore, inhibition of MET with increasing concentrations of 
MK2461 in both SUIT-2 and PANC-1 cells decreased the number of invading (Fig 6C) 
or migrating (Fig 6D) cells in a concentration-dependent manner. 
MK2461 regulated tumor progression in vivo 
Our results indicated that MK2461 significantly affected pancreatic cancer progression 
by disrupting the PCC-PSC interaction. To further characterize this process, I evaluated 
whether MK2461 inhibited tumor growth in a mouse xenograft model. PSCs alone are 
not tumorigenic; therefore, I co-injected SUIT-2 cells and PSCs into the right flanks of 
mice and SUIT-2 cells alone into the left flanks of mice, without using a PSC-alone 
control. One week after inoculation, mice were treated with MK2461 (20 mg/kg twice 
daily) or vehicle control for 20 days. No decreases in body weights of the mice were 
observed, and no treatment-related deaths were observed. In the co-injection model, 
MK2461 significantly inhibited tumor progression compared to vehicle, whereas in the 
SUIT-2-alone injection model, I did not observe any differences in tumor volumes 
between the MK2461-treated group and the vehicle-treated group (Fig. 7A). Consistent 
with this, I observed significant reductions in final tumor weights following MK2461 
treatment compared with vehicle treatment for the co-injection model (vehicle: 431 ± 
33.2 mg vs. MK2461: 320 ± 26.3 mg, P = 0.022) but not for tumors containing SUIT-2 
cells alone (vehicle: 259 ± 23.9 mg vs. MK2461: 247 ± 12.6 mg, P = 0.67). Therefore, 
MK2461 inhibited tumor growth only in the presence of PSCs.  
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Since MK2461 had antitumor effects in both SUIT-2 cells and PSCs in our in 
vitro study (Figs. 4A and 5A), I next examined whether MK2461 inhibited the 
proliferation of both SUIT-2 cells and PSCs using the markers Ki-67 and cytokeratin19 
(Fig. 7B and C). In co-injection models, the percentage of Ki-67-positive SUIT-2 cells 
was significantly higher in the vehicle group than in the MK2461 group, although no 
significant difference was observed between the vehicle group and MK2461 group in 
tumors arising from injection of SUIT-2 cells alone (Fig. 7D). Additionally, the 
percentage of Ki-67-positive PSCs was significantly higher in the vehicle group than in 
the MK2461 group (Fig. 7E). Similarly, the number of "-SMA-positive cells per field 








For the development of potential new therapeutic options for the treatment of 
pancreatic cancer, it is important to consider the tumor microenvironment. Therefore, in 
this study, I assessed the interactions between PCCs and PSC, which have been 
implicated in the progression to the malignant phenotype 20, 21, 32). I showed that PSC 
conditioned medium, which include secretions from the cells, promoted the 
proliferation of PCCs; conversely, conditioned medium from PCCs stimulated the 
proliferation of PSCs. Furthermore, I found that paracrine signaling was more effective 
at promoting proliferation than autocrine signaling, suggesting that components secreted 
from PSCs are essential to the progression of pancreatic cancer. Importantly, I also 
found that this effect was controlled by MK2461, a multitargeted kinase inhibitor, 
suggesting that MK2461 may represent a novel therapeutic agent for the treatment of 
pancreatic cancer.  
Previous studies have shown that PSCs exhibit increased secretion of growth 
factors, such as PDGF, HGF, CTGF, and FGF, and ECM components, including 
collagen type I and fibronectin, through the PCC-PSC interaction, resulting in 
enhancement of PCC proliferation 18). On the other hand, PCCs secrete growth factors 
such as PDGF, FGF, and TGF!1 to promote PSC proliferation and to stimulate the 
secretion of additional growth factors and ECM components from PSCs 10, 20). Therefore, 
I hypothesized that inhibition of RTK signaling could suppress the progression of 
pancreatic cancer.  
Using QTAP by LC-MS/MS, I revealed the expression levels of 15 RTKs 
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among 10 pancreatic cancer cell lines, three primary cultured PSCs, and 17 human 
pancreatic cancer tissues. I used purified plasma membrane fractions; therefore, the 
results accurately reflected the RTK expression levels presented on the cellular 
membrane. Importantly, my data demonstrated that EGFR, MET, and PDGFR! were 
expressed in pancreatic cancer cell lines, PSCs, and/or pancreatic tissues. Thus, my data 
supported that these RTKs likely played an important role in the PCC-PSC interaction.  
The expression levels of RTKs in pancreatic cancer tissues were almost 
equivalent to those of PSCs, consistent with the observation that 80% of pancreatic 
tissue consists of PSCs. Previous studies have shown that the expression of PDGFR! in 
PSCs correlates with the prognosis of patients with pancreatic cancer 33, 34). In this study, 
all of the established PSCs expressed PDGFR!. Moreover, previous studies have shown 
that PCCs express MET and that MET expression is correlated with prognosis 35-37). 
HGF secretion from PSCs has been shown to accelerate the progression of pancreatic 
cancer by increasing cell proliferation, invasion, and migration 38-40). My RTK profiling 
showed that MET was expressed not only in PCCs but also in PSCs. Interestingly, 
despite the high expression of MET in PCC, SUIT-2 cells alone are only weakly 
tumorigenic and essentially insensitive to MET inhibition in the absence of PSCs or 
PSC conditioned medium. This suggests that MET is inactive in PCCs and requires 
PSCs for activation. Hence, the HGF/MET pathway is thought to be important in 
mediating the interaction between PCCs and PSCs. 
PSCs are considered a potential target for pancreatic cancer therapy, and PSC 
proliferation induced by components secreted from PCCs is significantly inhibited by 
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PDGF-neutralizing antibodies 20). Therefore, targeting MET and PDGFR! should be 
more effective for the inhibition of PSC proliferation. Previous studies have also 
showed that inhibition of HGF/MET signaling contributes to the regulation of PCC 
progression in vitro and in vivo 41). In my pilot study, Tivantinib, MET inhibitor, 
suppressed SUIT-2 proliferation treated with PSC conditioned medium and imatinib, 
PDGFR inhibitor, and Tivantinib suppressed PSC proliferation treated with SUIT-2 
conditioned medium. Therefore, in this study, I focused on the effects of MK2461, a 
multikinase inhibitor targeting MET and PDGFR!, on the interaction between PSCs and 
PCCs. I did not use EGFR inhibitors because, although EGFR was detected in both 
pancreatic cancer cell lines and PSCs, EGF is not thought to be secreted from PSCs and 
the role of EGF/EGFR signaling is supposed to be small in the PSC-PCC interaction. In 
addition, in a clinical trial examining the efficacy of an EGFR inhibitor in the treatment 
of pancreatic cancer, overall survival was prolonged only 2 weeks by adding EGFR 
inhibitor to gemcitabine compared with gemcitabine only, so EGFR inhibitor is not 
used in standard pancreatic cancer therapy42). Furthermore, in my pilot study, Gefitinib, 
EGFR inhibitor, had no effect on SUIT-2 and PSC proliferation. 
In this study, I found that MK2461 significantly inhibited PCC proliferation 
induced by PSC conditioned medium. Moreover, MET and downstream signaling 
components, such as ERK1/2 and AKT, were activated by PSC conditioned medium, 
and the phosphorylation of these enzymes was suppressed by MK2461 treatment. 
Consistently with this, MK2461 significantly inhibited PSC proliferation in the 
presence of PCC conditioned medium compared to serum-free medium, and MET, 
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PDGFR!, ERK1/2, and AKT were activated by PCC conditioned medium, but 
inactivated by treatment with MK2461. Since MET was activated by PCC conditioned 
medium, these data suggested that HGF was secreted from both PCCs and PSCs and 
contributed to autocrine signaling.   
An important observation in this model was that MK2461 significantly 
inhibited both PCC and PSC proliferation, disrupting the PCC-PSC interaction. 
Previous studies have focused on the inhibition of cell growth for either PCCs or PSCs. 
In the studies focusing on the tumor microenvironment, inhibiting PSC proliferation and 
suppressing the secretion of growth factors and other components from PSCs have been 
shown to result in inhibition of pancreatic cancer progression or enhancement of 
chemotherapeutic effects 15, 16, 43). In this study, MK2461 was found to contribute to the 
reduction in PSC secretion by inhibiting PSC proliferation. Furthermore, MK2461 also 
inhibited the activation of MET, which was highly expressed in PCCs and was activated 
by PSC conditioned medium. Therefore, MK2461 was thought to exert substantial 
inhibitory effects on pancreatic cancer progression.   
PDGF and HGF have been reported to promote cancer cell invasion and 
migration 39, 44), and previous studies have indicated that PSC conditioned medium 
promotes PCC invasion and migration 18, 21, 32), which was confirmed by the results of 
this study. I also revealed that MK2461 inhibited the effects of PSC conditioned 
medium on PCC invasion and migration. Therefore, future studies should assess 
whether MK2461 reduces the incidence of metastasis using orthotopic xenograft 
models.  
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In this in vivo study, I revealed that MK2461 significantly inhibited tumor 
growth in co-injection models and that the effects of MK2461 were not observed in 
tumors derived from SUIT-2 cells alone. These findings were consistent with my in 
vitro proliferation assays. Surprisingly, tumor volumes in the MK2461 group in the 
co-injection model were equivalent to those in the vehicle group in the tumors derived 
from injection of SUIT-2 cells alone; therefore, these findings suggested that MK2461 
strongly inhibited tumor growth by disrupting the PCC-PSC interaction. Targeting 
HGF/MET signaling with a monovalent monoclonal antibody against MET was 
reported to inhibit HGF paracrine-driven pancreatic tumor growth in a xenograft model 
41). However, while SUIT-2 cells secreted HGF, MK2461 did not suppress tumor 
progression in our mouse model in which SUIT-2 cells were injected alone. These data 
suggested that the paracrine pathway was essential to the growth of PCCs, consistent 
with the results of our in vitro study. 
In previous study, it is reported that the PCC-PSC interaction which work as 
paracrine pathway plays an important role in pancreatic cancer progression9, 10). In 
contrast, latest studies showed opposite function of stroma that stroma act to restrain, 
rather than support in pancreatic cancer progression45, 46). From theses studies, stroma is 
supposed to have dual function. It is supposed that MK2461 regulated stromal function 
that promote pancreatic cancer progression, resulted in suppressing pancreatic cancer 
progression.   
Immunofluorescence staining for Ki-67 showed that MK2461 inhibited both 
PCC and PSC proliferation in co-injection models, but not in tumors derived from 
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injection of SUIT-2 cells alone. These results confirmed the reduction in tumor volume 
in the co-injection model. In addition, my results suggested that MK2461 inhibited PSC 
proliferation more strongly than PCC proliferation. In addition, the number of 
"-SMA-positive cells in the MK2461 group was less than 30% that of the vehicle group, 
whereas the number of cytokeratin19-positive cells was equivalent between the two 
groups (data not shown). This indicated that the area occupied by PSCs in tumors was 
reduced, consistent with the results of immunofluorescence staining for Ki-67.  
Clinically, our data may have implications in the field of personalized medicine. 
Indeed, I showed that MET exhibited differential expression in pancreatic cancer tissues, 
suggesting that MK2461 may be more effective in some patients (i.e., those expressing 
high levels of MET) than in others. These conjectures will need to be explored further 
in additional studies. 
In conclusion, profiling of 15 RTKs showed that PDGFR! and MET were 
highly expressed in PCCs and PSCs. Moreover, MK2461 treatment effectively inhibited 
tumor progression in pancreatic cancer by disrupting the PCC-PSC interaction in vitro 
and in vivo. Therefore, MK2461 may represent a novel chemotherapeutic agent for the 
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Figure 1. !-SMA expression in established PSCs and effects of the PCC-PSC 
interaction on cell proliferation. 
Immunofluorescence staining of "-SMA and vimentin in established PSCs. Red: 
"-SMA; green: vimentin; blue: DAPI. Scale bar, 100 µm. (B) Protein lysates from PSCI, 
PSCII, or PSCIII and TIG-1-20 were analyzed for "-SMA expression by western 
blotting. GAPDH served as a loading control. (C) Effects of PSCI, PSCII, and PSCIII 
conditioned medium on PCC (SUIT-2 and PANC-1 cell) proliferation. Proliferation 
assays were performed 48 h after adding PSC conditioned medium. SFM, serum-free 
medium; CM, condition medium; *: P < 0.05, ***: P < 0.001 versus the serum-free 
medium control. (D) Effects of PCC (SUIT-2 and PANC-1 cell) conditioned medium 
on PSC (PSCI and PSCII) proliferation. Proliferation assays were performed 48 h after 
adding PCC conditioned medium. SFM, serum-free medium; CM, condition medium; 
*: P < 0.05, **: P < 0.01, ***: P < 0.001 versus the serum-free medium control. 
Figure 2. Comparison of cell proliferation induced by paracrine and autocrine 
secretions. 
(A) Proliferation assays were performed in SUIT-2 and PANC-1 cells 48 h after adding 
PSC conditioned medium. CM, condition medium; *: P < 0.05 versus PCC conditioned 
medium. (B) Proliferation assays were performed 48 h after adding PSC conditioned 
medium. CM, condition medium; *: P < 0.05, **: P < 0.01 versus PSC conditioned 
medium. 
Figure 3. Expression levels of RTKs in plasma membrane fractions. 
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(A) Comparison of RTK (EGFR, PDGFR!, and MET) expression levels between 
pancreatic cancer cell lines, PSCs, and pancreatic cancer tissues. PT1-17 indicates the 
pancreatic cancer tissue obtained from Patient 1-17. (B) Comparison of RTK (EGFR, 
PDGFR!, and MET) expression levels between pancreatic cancer tissues and normal 
pancreatic tissues. Pancreatic cancer tissue and normal pancreatic tissue was separated 
from the sample given by Patient 1-3 and used for the assay. Each bar represents the 
protein expression level in the plasma membrane fraction (mean ± SEM).  
Figure 4. MK2461 inhibited the effects of PSC conditioned medium on PCC 
proliferation and suppressed the activation of MET and downstream signaling.  
(A) Proliferation assays were performed in SUIT-2 and PANC-1 cells 48 h after adding 
PSC conditioned medium (0.5 mg/mL) and MK2461 (0, 0.1, 1, and 3 µM). *: P < 0.05, 
**: P < 0.01, ***: P < 0.001 versus the untreated control. (B) Comparison of PCC 
(SUIT-2 and PANC-1 cell) growth inhibition by MK2461 in cells treated with PSC 
conditioned medium (0.5 mg/mL) or serum-free medium. Cell growth inhibition was 
calculated as the percent of absorbance differences between 0 µM and MK2461 (0.1, 1, 
and 3 µM). Proliferation assays were performed 48 h after adding PSC conditioned 
medium (0.5 mg/mL) and MK2461 (0, 0.1, 1, and 3 µM). *: P < 0.05, **: P < 0.01, 
***: P < 0.001 versus the untreated control. (C) Western blotting of signaling 
intermediates. PCCs (SUIT-2 and PANC-1 cells) were incubated with MK2461 (1 µM) 
for 4 h, stimulated with PSC conditioned medium (0.5 mg/mL) for 10 min, then lysed. 
GAPDH served as the loading control. CM, condition medium 
Figure 5. MK2461 inhibited the effects of PCC conditioned medium on PSC 
39 
proliferation and suppressed activation of PDGFR", MET, and downstream 
signaling. 
(A) Proliferation assays were performed in SUIT-2 and PANC-1 cells 48 h after adding 
PCC conditioned medium (0.5 mg/mL) and MK2461 (0, 0.1, and 1 µM). *: P < 0.05, 
**: P < 0.01, ***: P < 0.001 versus the untreated control. (B) Comparison of PSC 
(PSCI and PSCII) growth inhibition by MK2461 in SUIT-2 and PANC-2 cells treated 
for 48 h with conditioned medium (0.5 mg/mL) or serum-free medium. Cell growth 
inhibition was calculated as a percent of absorbance differences between untreated cells 
and cells treated with MK2461 (0.1 and 1 µM). *: P < 0.05, **: P < 0.01, ***: P < 
0.001 versus the untreated control. (C) Western blotting of signaling intermediates. 
PSCs were incubated with MK2461 (3 µM) for 4 h, stimulated with SUIT-2 cell 
conditioned medium (0.1 mg/mL) for 10 min, then lysed. GAPDH served as the loading 
control. CM, condition medium 
Figure 6. PSC conditioned medium promoted PCC invasion and migration in an 
MK2461-dependent manner. 
(A) Invasion assays were performed in SUIT-2 and PANC-1 cells 48 h after adding 
PSC conditioned medium. SFM, serum-free medium; CM, condition medium; **: P < 
0.01, ***: P < 0.001 versus the serum-free medium control. Scale bar, 50 µm. (B) 
Migration assays were performed in SUIT-2 and PANC-1 cells 24 h after adding PSC 
condition medium (0.1 or 0.5 mg/mL). SFM, serum-free medium; CM, condition 
medium; **: P < 0.01, ***: P < 0.001 versus the serum-free medium control. Scale bar, 
50 µm. (C) Invasion assays were performed in SUIT-2 and PANC-1 cells 48 h after 
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adding PSC conditioned medium (0.5 mg/mL) and MK2461 (0, 0.1, and 1 µM). **: P < 
0.01, ***: P < 0.001 versus the untreated control. Scale bar, 50 µm. (D) Migration 
assays were performed in SUIT-2 and PANC-1 cells 24 h after adding PSC condition 
medium (0.5 mg/mL) and MK2461 (0, 0.1, and 1 µM). *: P < 0.05, **: P < 0.01, ***: P 
< 0.001 versus the untreated control. Scale bar, 50 µm. 
Figure 7. MK2461 regulated tumor progression in vivo. 
The effects of MK2461 on tumor progression were assessed using a xenograft model. 
SUIT-2 cells and PSCs were subcutaneously co-injected into the right flanks of mice, 
while SUIT-2 cells were injected alone into the left flanks of mice. One week later, 
mice were administered vehicle or MK-2461 (20 mg/kg) twice daily for 20 days by oral 
gavage. (A) Co-injection model. ***: P < 0.001. SUIT-2 injection alone. (B) 
Immunofluorescence staining for cytokeratin19 + Ki-67 (top panel) and cytokeratin19 + 
DAPI (bottom panel). Red: cytokeratin19; green: Ki-67; blue: DAPI. Scale bar, 50 µm. 
(C) Immunofluorescence staining for "-SMA + Ki-67 (top panel) and for "-SMA + 
DAPI (bottom panel). Red: "-SMA; green: Ki-67; blue: DAPI. Scale bar, 50 µm. White 
arrows indicate PSCs stained for both "-SMA and Ki-67. (D) The percent of 
Ki-67-positive cells in cytokeratin19-positive cells. ***: P < 0.001. (E) The percent of 
Ki-67-positive cells in "-SMA-positive cells. ***: P < 0.001. (F) The number of 






"-SMA   Alpha smooth muscle actin   
BSA   Bovine serum albumin 
CTGF  Connective tissue growth factor 
DMEM  Dulbecco’s modified eagle medium 
ECM   Extracellular matrix 
EGFR  Epidermal growth factor receptor 
EMT            Epithelial mesenchymal transition 
ERK            Extracellular signal-regulated kinase 
FGF      Fibroblast growth factor 
FGFR           Fibroblast growth factor receptor 
GAPDH         Glyceraldehyde-3-phosphate dehydrogenase 
GRB2           Growth factor receptor-bound protein-2 
HER2           Human epidermal growth factor receptor-2 
HER3           Human epidermal growth factor receptor-3 
HGF         Hepatocyte growth factor  
HPLC  High performance liquid chromatography 
IGF   Insulin-like growth factor 
IGFR            Insulin-like growth factor receptor  
LC-MS/MS Liquid chromatography tandem mass spectrometry 
MRM  Multi-channel reaction monitoring 
MEK            MAPK/ERK kinase 
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MET   Hepatocyte growth factor receptor 
mTOR          Mammalian target of rapamycin 
MRM  Multiple reaction monitoring 
NF            Normal fibroblast 
PBS          Phosphate buffered saline  
PCC          Pancreatic cancer cell 
PSC  Pancreatic stellate cell 
PDGF           Platelet-derived growth factor 
PDGFR          Platelet-derived growth factor receptor 
PI3K            Phosphatidylinositol 3 kinase 
QTAP  Quantitative targeted absolute proteomics 
SDS-PAGE  Sodium lauryl sulfate poly-acrylamide gel electrophoresis 
SEM  Standard error of the mean 
SRM  Selected reaction monitoring 
TBS            Tris buffered saline 
TGF!? ?  Transforming growth factor !  
VEGF       Vascular endothelial growth factor 
VEGFR      Vascular endothelial growth factor receptor 
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Conditions of MRM were optimized for high signal intensity by direct injection of peptide solution 
into the mass spectrometer through a turbo ion spray source. Theoretical m/z values of doubly charged 
ions of intact peptides (Q1) were postulated as precursor ions. Four singly charged fragment ions (Q3) 
were derived from each precursor ion. In peptide sequence, letters with asterisks and under bars 
indicate amino acid residues labeled with stable isotope (13C and 15N). MRM, Multi-channel reaction 
monitoring; st, standard peptide; is, internal peptide; DP, declustering potential; CE, collusion energy  
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Table 2. Expression profile of RTKs in plasma membrane fraction 
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The quantitative values were calculated from peak area ratio of analyte to stable isotope-labeled peptides as internal standards. The expression levels of each protein was 
determined as the average of three to four quantitative values from four SRM/MRM transitions of one analysis (fmol / µg protein). Each sample was measured three times and the 
value represents the mean ± SEM (n=3). U.L.Q., under the limit of quantification 
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